Gilead’s Once-Daily HIV Combo Receives Priority Status; Accelerates Race With GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
The fixed-dose co-formulation of Viread/Emtriva has an estimated user fee deadline of Sept. 12; a decision on GSK’s combo is expected in August. Results from a study of Viread, Emtriva and Sustiva are due by year end, Gilead said.